biosimilars

Views & Analysis

New technology is now the beating heart of patient care

Patient care and healthcare provision have always appeared among society’s top priorities, but keeping people well came into sharp focus during the pandemic.

Views & Analysis

Osteoporosis treatment options - down to the bare bones

It is World Osteoporosis Day this month, and Ben Hargreaves takes a look at what treatment options look like for patients living with the disease.

News

Novartis decides Sandoz' future – and it's a spin-out

After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company.

R&D

Challenges and opportunities in the off-patent sector: the p...

In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Rebecca Guntern, vice president of medicines for Europe at Sandoz.

News

Novartis faces tougher decision on Sandoz, as finances recov...

Novartis said this morning that it remains on course to make a decision on the future of its generics business Sandoz by the end of the year, amid signs of a "return towards normal business

Market Access